Displacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumab

QR Code

Displacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumab

Sukhpal Singh Sandhu1,2, Sridhar Manvikar1, David Henry William Steel11Sunderland Eye Infirmary, Sunderland, United Kingdom; 2Centre for Eye Research Australia, Melbourne, AustraliaBackground/aims: To evaluate retrospectively the clinical outcomes of patients presenting with submacular hemorrhage (S...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Sukhpal Singh Sandhu, Sridhar Manvikar, David Henry William Steel
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2010
Sujets:	Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/b9af66fadac34d249eed5524dbc28ff3
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Intravitreal ranibizumab in treating extensive traumatic submacular hemorrhage
par: Abdul-Salim I, et autres
Publié: (2013)

Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
par: Karagiannis D, et autres
Publié: (2017)

Long-Term Outcome of Eyes with Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration
par: Setsuko Kawakami, et autres
Publié: (2021)

Pneumatic displacement with intravitreal bevacizumab for massive submacular hemorrhage due to polypoidal choroidal vasculopathy
par: Kitahashi M, et autres
Publié: (2014)

The Mechanism of Gas in Submacular Hemorrhage [Letter]
par: Özyol E
Publié: (2021)

Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration
par: Iannetta D, et autres
Publié: (2021)

Efficacy of pneumatic displacement with 40-degree downward gaze positioning for treatment of submacular hemorrhage: report of two cases
par: Nakajima M, et autres
Publié: (2012)

Long-Term Favorable Visual Outcomes in Patients with Large Submacular Hemorrhage
par: Iyer PG, et autres
Publié: (2021)

Visual Outcomes and Prognostic Factors of Large Submacular Hemorrhages Secondary to Polypoidal Choroidal Vasculopathy
par: Matsuo Y, et autres
Publié: (2021)

Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy
par: Dimopoulos S, et autres
Publié: (2015)

Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
par: Boone NW, et autres
Publié: (2012)

Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration
par: Luis Arias, et autres
Publié: (2010)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
par: Canan H, et autres
Publié: (2014)

Movement of intraretinal fluid from distant branch retinal vein occlusion to the submacular space
par: Otani T, et autres
Publié: (2013)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
par: Suzuki H, et autres
Publié: (2017)

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
par: Michalska-Małecka K, et autres
Publié: (2016)

Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population
par: Basheer K, et autres
Publié: (2015)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
par: Fouda SM, et autres
Publié: (2017)

Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA.
par: Mitsunori Ishiguro, et autres
Publié: (2010)

Treatment of peripheral exudative hemorrhagic chorioretinopathy by intravitreal injections of ranibizumab
par: Takayama K, et autres
Publié: (2012)

Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
par: Fujii A, et autres
Publié: (2014)

Diabetic papillopathy with macular edema treated with intravitreal ranibizumab
par: Kim M, et autres
Publié: (2013)

Intravitreal ranibizumab for symptomatic drusenoid pigment epithelial detachment without choroidal neovascularization in age-related macular degeneration
par: Roberto Gallego-Pinazo, et autres
Publié: (2011)

Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration
par: Nishimura T, et autres
Publié: (2012)

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration [Corrigendum]
par: Michalska-Małecka K, et autres
Publié: (2016)

Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population: letter to the editor
par: Stewart MW
Publié: (2015)

Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.
par: Wei Wang, et autres
Publié: (2014)

Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration
par: Pukhraj Rishi, et autres
Publié: (2011)

A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration
par: Williams PD, et autres
Publié: (2012)

Treatment of age-related macular degeneration: focus on ranibizumab
par: Martin S Spitzer, et autres
Publié: (2008)

High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration
par: Cengiz Tuerksever, et autres
Publié: (2021)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
par: Fong AH, et autres
Publié: (2013)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
par: Dervenis N, et autres
Publié: (2016)

Predictor of Early Remission of Diabetic Macular Edema under As-Needed Intravitreal Ranibizumab
par: Tatsuya Yoshitake, et autres
Publié: (2019)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
par: Dimitrios A Karagiannis, et autres
Publié: (2009)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
par: Hirakata T, et autres
Publié: (2016)

Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life
par: Inoue M, et autres
Publié: (2014)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration [Corrigendum]
par: Dervenis N, et autres
Publié: (2016)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
par: Pessoa B, et autres
Publié: (2021)

Testing the clinical value of multifocal electroretinography and microperimetry and the effects of intravitreal therapy with ranibizumab on macular function in the course of wet age-related macular degeneration: a 1-year prospective study
par: Reinsberg M, et autres
Publié: (2017)